X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs AJANTA PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA AJANTA PHARMA AUROBINDO PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 13.9 20.4 68.1% View Chart
P/BV x 2.8 3.5 79.9% View Chart
Dividend Yield % 0.4 1.0 44.5%  

Financials

 AUROBINDO PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
AJANTA PHARMA
Mar-19
AUROBINDO PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs8091,422 56.9%   
Low Rs504898 56.1%   
Sales per share (Unadj.) Rs281.1233.5 120.4%  
Earnings per share (Unadj.) Rs41.444.0 94.1%  
Cash flow per share (Unadj.) Rs50.952.2 97.6%  
Dividends per share (Unadj.) Rs2.509.00 27.8%  
Dividend yield (eoy) %0.40.8 49.1%  
Book value per share (Unadj.) Rs199.4255.1 78.2%  
Shares outstanding (eoy) m585.8888.02 665.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x2.35.0 47.0%   
Avg P/E ratio x15.926.4 60.2%  
P/CF ratio (eoy) x12.922.2 58.0%  
Price / Book Value ratio x3.34.5 72.4%  
Dividend payout %6.020.5 29.5%   
Avg Mkt Cap Rs m384,630102,081 376.8%   
No. of employees `00017.36.8 254.9%   
Total wages/salary Rs m21,3084,307 494.7%   
Avg. sales/employee Rs Th9,500.73,022.6 314.3%   
Avg. wages/employee Rs Th1,229.4633.4 194.1%   
Avg. net profit/employee Rs Th1,397.9569.1 245.7%   
INCOME DATA
Net Sales Rs m164,66620,554 801.1%  
Other income Rs m1,020211 483.8%   
Total revenues Rs m165,68620,765 797.9%   
Gross profit Rs m37,7185,664 665.9%  
Depreciation Rs m5,580721 774.1%   
Interest Rs m77712 6,700.0%   
Profit before tax Rs m32,3805,143 629.6%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,1831,273 642.8%   
Profit after tax Rs m24,2293,870 626.1%  
Gross profit margin %22.927.6 83.1%  
Effective tax rate %25.324.8 102.1%   
Net profit margin %14.718.8 78.2%  
BALANCE SHEET DATA
Current assets Rs m121,87811,812 1,031.8%   
Current liabilities Rs m86,8063,776 2,298.6%   
Net working cap to sales %21.339.1 54.5%  
Current ratio x1.43.1 44.9%  
Inventory Days Days13077 167.8%  
Debtors Days Days6882 83.8%  
Net fixed assets Rs m81,03714,398 562.8%   
Share capital Rs m586175 334.0%   
"Free" reserves Rs m116,21822,277 521.7%   
Net worth Rs m116,80422,452 520.2%   
Long term debt Rs m4,5127 68,363.6%   
Total assets Rs m211,05226,962 782.8%  
Interest coverage x42.7444.3 9.6%   
Debt to equity ratio x00 13,140.9%  
Sales to assets ratio x0.80.8 102.3%   
Return on assets %11.814.4 82.3%  
Return on equity %20.717.2 120.4%  
Return on capital %27.423.0 119.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72710,682 755.8%   
Fx outflow Rs m34,7002,102 1,650.9%   
Net fx Rs m46,0278,580 536.5%   
CASH FLOW
From Operations Rs m19,5483,748 521.6%  
From Investments Rs m-19,570-2,228 878.3%  
From Financial Activity Rs m8,642-1,475 -586.0%  
Net Cashflow Rs m8,92245 19,739.2%  

Share Holding

Indian Promoters % 54.1 73.8 73.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 1.6 512.9%  
FIIs % 27.7 7.6 364.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 17.0 60.0%  
Shareholders   69,601 20,968 331.9%  
Pledged promoter(s) holding % 8.6 4.4 195.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   DISHMAN PHARMA  CADILA HEALTHCARE  SUVEN LIFESCIENCES  DR. DATSONS LABS  WOCKHARDT  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; HDFC Bank and Yes Bank Top Gainers(09:30 am)

Asian share markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 1.2% while the Hang Seng is up 1%.

Related Views on News

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Driverless Cars are Here. And This Tiny Company is in the Lead...(The 5 Minute Wrapup)

Jul 17, 2019

This future-ready company thrives on the pace of technological change.

Here's Why This Smallcap Will Beat the Big Autos in the EV Race(Profit Hunter)

Jul 16, 2019

As the conventional auto sector faces existential crisis, my latest smallcap recommendation is all set to ride the electric vehicle disruption and rise in new age vehicles.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jul 24, 2019 12:01 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - DR. REDDYS LAB COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS